SCHEMBL1813161

SCHEMBL1813161

Cc1cc(C(OS(C)(=O)=O)(C(F)(F)F)C(F)(F)F)cc(C)c1NC(=O)c1cccc(NC(=O)c2ccc(Cl)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 3/20 0.52
RHOC P08134 1/20 0.51
RHOA P61586 1/20 0.51
ADORA3 P0DMS8 1/20 0.46
ADORA2A P29274 1/20 0.46
ADORA2B P29275 1/20 0.46
ADORA1 P30542 1/20 0.46
PPARG P37231 4/20 0.45
NR1H4 Q96RI1 4/20 0.45
PPARD Q03181 2/20 0.45
PPARA Q07869 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HTT P42858 2/20 0.43
HPGD P15428 1/20 0.43
MAPT P10636 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2260905 0.93 KCNK3 (0.51) KCNK3RHOCRHOAADORA3ADORA2A
SCHEMBL2258597 0.91 KCNK3 (0.49) KCNK3MEN1KMT2ARAB9ANPC1
SCHEMBL1818337 0.89 MAPT (0.43) KCNK3RHOCRHOAMEN1KMT2A
SCHEMBL1819533 0.88 KCNK3 (0.54) KCNK3RXFP1MEN1KMT2ARAB9A
SCHEMBL2259443 0.86 RAB9A (0.45) KCNK3RXFP1MEN1KMT2ARAB9A
SCHEMBL1818358 0.85 MEN1 (0.52) KCNK3RXFP1MEN1KMT2ARAB9A
SCHEMBL1812611 0.85 KMT2A (0.50) KCNK3RXFP1MEN1KMT2ARAB9A
SCHEMBL1821034 0.83 KCNK3 (0.58) KCNK3RHOCRHOAPPARGNR1H4
SCHEMBL2261615 0.82 BRAF (0.44) KCNK3RXFP1KCNK9
SCHEMBL1812039 0.78 ALDH1A1 (0.51) RXFP1MEN1KMT2ARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201603-A1 Novel Acylaminobenzamide Derivatives BAYER CROPSCIENCE AG (DE) 2011-08-18 US disclosed
EP-2318358-A2 ACYLAMINOBENZAMIDE DERIVATIVES Bayer CropScience AG (DE) 2011-05-11 EP disclosed
WO-2010015355-A2 NOVEL ACYLAMINOBENZAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201603-A1 Novel Acylaminobenzamide Derivatives KCNB1, KCNA5, KCNA7 KCNK3 174/4885RHOC 2828/4885RHOA 3401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.